I
nfluenza A virus (IAV) is the causative agent of mostly mild to moderate seasonal respiratory infections and several pandemic outbreaks, the most recent of which was reported in 2009. Previous IAV pandemics were associated with an enormous death toll; for example, the 1918 H1N1 pandemic affected hundreds of millions of people globally and resulted in~50 million deaths. 1 Microbiologic analyses of patient samples revealed a strong incidence of bacterial pathogens in fatal complications of viral infection. 2 To date, many pieces of epidemiologic and experimental evidence reveal pronounced susceptibility to detrimental bacterial superinfection in IAVinfected individuals. The physiologic mechanisms underlying the fatal synergism between IAV and opportunistic respiratory bacterial pathogens are so far incompletely understood. Among these mechanisms, the depletion 3 or dysfunction 4 of professional phagocytes, attenuation of antimicrobial production 5 or desensitization to microbial-associated molecular patterns (MAMPs) 6 are just a few examples indicating the deactivation of airway antimicrobial defense during IAV infection.
Interleukin 33 (IL-33) is one of 11 members of the IL-1 family of cytokines. Although intracellular IL-33 can act as a potent regulator of stimulated and constitutive gene expression, extracellular IL-33 has pleiotropic downstream effects on cells expressing the specific (primary) IL-33 receptor ST2 (for example, fibroblasts, mast cells, T helper 2 (T H 2) cells, resident macrophages, DCs, and type 2 innate lymphoid cells (ILC2)). 7 Furthermore, IL-33 is released after cellular injury and (after enzymatic processing) can thus act as a conserved endogenous danger molecule, also termed 'alarmin'. 8 IL-33 signaling is reported to have detrimental effects in chronic, noncommunicable lung ailments, whereas its role during respiratory infection greatly differs for the various pathogens and the correlating immune responses mounted against them. 9 Importantly, the impact of a preceding IAV infection on IL-33 production during secondary bacterial pneumonia and, vice versa, the physiologic effects of IL-33 on the course of the secondary infection have so far not been addressed.
A recent report by Robinson et al. 10 in Mucosal Immunology highlights a novel role of the alarmin cytokine IL-33 in influenza A virus (IAV)-induced predisposition to secondary bacterial pneumonia (Advance Online Publication, AOP) ( Figure 1) . The authors employed a murine model in which bacterial superinfection was performed at d 6 post-IAV infection, which is the window of hypersusceptibility to secondary infection with opportunistic bacterial pathogens. 4, 11, 12 They demonstrated that antecedent IAV infection markedly attenuates the pulmonary IL-33 response to Gram-positive (S. aureus) and Gram-negative (P. aeruginosa) bacteria at the RNA and protein levels. By using systemic (injection of recombinant cytokine) or local (pulmonary adenoviral gene-transfer) delivery of IL-33 into IAV/S. aureus co-infected mice, the authors demonstrated a definite role of IL-33 in antagonizing microbial outgrowth during respiratory coinfection. Consistent with previous studies, the authors reported that IL-33 administration correlated with the induction of a type 2 immune response in co-infected lungs that was characterized by increased transcript and protein levels of relevant cytokines (IL-13, IL-5 and eotaxin) and hallmark molecules of epithelial mucus production (Clca3 and Muc5b). Interestingly, by demonstrating that therapeutic IL-33 administration in lymphocyte-deficient mice (Rag2 − / − Il2rg − / − mice) improved bacterial clearance during co-infection in a similar manner as observed in wild-type mice, the authors demonstrated that the antibacterial function of IL-33 was orchestrated by nonlymphocytic cells. In this context, the authors analyzed a possible role of IL-33 on relevant pathways orchestrated by phagocytic myeloid leukocytes. Although IL-33 proved ineffective in inducing expression of relevant macrophage scavenger receptors, the administration of this cytokine significantly increased the numbers of intrapulmonary neutrophilic granulocytes and the expression of the microbicide neutrophil elastase during co-infection. Finally, following the hypothesis that IL-33 exerts its antibacterial effects through neutrophils, the authors chose an experimental setup in which IL-33-treated mice were systemically depleted of neutrophils by prior injection of a neutrophil-specific antibody. On the one hand, these experiments revealed that IL-33 controls bacterial outgrowth in the lung partly via neutrophils given that lungs of neutrophil-depleted mice that received therapeutic IL-33 treatment displayed increased pulmonary bacterial burden compared with neutrophil-sufficient IL-33-treated controls. On the other hand, the comparison of lung bacterial burden in neutrophil-depleted mice that were recipients or non-recipients of therapeutic IL-33 strikingly revealed that in the absence of neutrophils exogenous supplementation of this cytokine greatly decreased lung bacterial burden during respiratory IAV/S. aureus co-infection to almost similar levels as that observed in neutrophil-sufficient IL-33-treated mice. This finding highlights the central role of IL-33 in orchestrating mucosal antibacterial immunity executed by neutrophils and other leukocytes and/or structural cells during influenza-associated secondary bacterial pneumonia.
In conclusion, this study disclosed two important points. First, we identified the IL-33/ST2 axis as a mechanism affected by IAV-mediated attenuation of pulmonary antibacterial immunity. For future investigations, it remains of utmost interest to clarify whether this effect originates from the loss of relevant IL-33 producers, for example, alveolar macrophages or lung epithelial cells 13 (both are vastly depleted during acute influenza infection 3,14 ), or rather from virus-induced alterations in networks that control transcription and release and/or stability of bioactive IL-33 in the co-infected lung. Second, it was demonstrated that neutrophils are one -but not the only-cellular subset targeted by therapeutic IL-33 treatment during co-infection. As the IL-33 receptor is expressed on various cell types (for example, DCs, macrophages, ILC2 and fibroblasts), the identification of the cellular sentinels and the implications of IL-33 signaling in these cells for effective mucosal immunity is a prerequisite to identify essential antibacterial networks and thus possible targets to interfere with the fatal synergism between influenza A virus and secondary bacterial pathogens in the future. Therapeutic strategies aiming at the reinforcement of the mucosal barrier (in addition to recruiting functional phagocytes) might be one future option to protect the pre-diseased lung from microbial outgrowth. Robinson et al. 10 demonstrated epithelial activation (induction of mucus production-related pathways) to be one hallmark of IL-33 treatment. Given that lung epithelial cells are critically involved in locally shaping antimicrobial immune responses, 15, 16 Figure 1 Central roles of IL-33 in the pathogenesis of secondary bacterial pneumonia during influenza A virus (IAV) infection. Respiratory infection with opportunistic bacteria elicits a robust pulmonary IL-33 response, which is strongly attenuated in IAV pre-infected lungs (light red: single infection, dark red: co-infection). Therapeutic reconstitution of pulmonary antibacterial immunity during co-infection is mediated by IL-33 treatment. IL-33 elicits a type 2 immune response in co-infected lungs, which is dependent on type 2 innate lymphoid cells (ILC2) and/or T helper 2 (T H 2) cells. IL-33-mediated antibacterial immunity in co-infected lungs is orchestrated by neutrophildependent and neutrophil-independent pathways. elucidating the role of the lung epithelium as a secondary effector of IL-33/ ST2-orchestrated airway mucosal immunity is critical for integrating the hitherto existing results into a complete view on the implications of the IL-33/ST2 axis in IAV/bacterial co-infections.
